Benzinga | Mar 12, 2021 06:30AM EST

HC Wainwright & Co. Upgrades Intercept Pharmaceuticals to Neutral, Lowers Price Target to $21

HC Wainwright & Co. analyst Ed Arce upgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Sell to Neutral and lowers the price target from $25 to $21.